<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sulbactam and durlobactam: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sulbactam and durlobactam: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sulbactam and durlobactam: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="141617" href="/d/html/141617.html" rel="external">see "Sulbactam and durlobactam: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58588637"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Xacduro</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58262661"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Beta-Lactam;</li>
<li>
                        Beta-Lactamase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F58289048"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58f09831-e1d9-4d13-a555-4196b8a7ce81">Pneumonia, hospital-acquired or ventilator-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired or ventilator-associated</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve use for patients with <i>A. baumannii-calcoaceticus</i> complex infection.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Sulbactam 1 g/durlobactam 1 g every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37182534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37182534'])">Ref</a></span>). Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521441'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F58289056"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Estimation of kidney function for the purpose of drug dosing should be done using the Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 45 to 129 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 44 mL/minute: <b>IV:</b> Sulbactam 1 g/durlobactam 1 g every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 29 mL/minute: <b>IV:</b> Sulbactam 1 g/durlobactam 1 g every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;15 mL/minute: <b>IV:</b> Loading dose: Sulbactam 1 g/durlobactam 1 g every 12 hours for 3 doses, then sulbactam 1 g/durlobactam 1 g once daily. <b>Note:</b> For patients whose CrCl declines to &lt;15 mL/minute after therapy has been initiated, administer once daily without loading dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Augmented renal clearance (CrCl ≥130 mL/minute):<b> IV:</b> Sulbactam 1 g/durlobactam 1 g every 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis, intermittent (thrice weekly): Dialyzable (sulbactam: 41%; durlobactam: 33%): <b>IV:</b> Loading dose: Sulbactam 1 g/durlobactam 1 g every 12 hours for 3 doses, then sulbactam 1 g/durlobactam 1 g once daily; administer after hemodialysis on dialysis days. <b>Note:</b> For patients who require hemodialysis after therapy has been initiated, administer once daily without loading dose.</p></div>
<div class="block doha drugH1Div" id="F58289059"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F58289049"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F58265383"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiac: Cardiac arrhythmia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (6%; including increased serum creatinine, renal failure syndrome, toxic nephrosis)</p></div>
<div class="block coi drugH1Div" id="F58262664"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Severe hypersensitivity to sulbactam, durlobactam, any component of the formulation, or other beta-lactam antibacterial drugs.</p></div>
<div class="block war drugH1Div" id="F58289020"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions, including serious skin reactions and fatal hypersensitivity (anaphylactic) reactions, have occurred in patients receiving beta-lactams; risk is increased in patients with a history of beta-lactam and/or multiple allergen hypersensitivity. Hypersensitivity reactions to sulbactam and durlobactam have been observed; prior to therapy, obtain history of previous hypersensitivity reactions to all beta-lactams and other allergens. Discontinue therapy and initiate appropriate treatment if signs and symptoms of anaphylaxis or severe hypersensitivity occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>Clostridioides difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p></div>
<div class="block foc drugH1Div" id="F58588638"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xacduro: Sulbactam sodium 1 g and durlobactam sodium 1 g (3 ea)</p></div>
<div class="block geq drugH1Div" id="F58588636"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58659615"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Xacduro Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1-1 g (per each): $190.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F58289060"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer by IV infusion over 3 hours; if refrigerated prior to administration, bring to room temperature for 15 to 30 minutes immediately prior to administration.</p></div>
<div class="block use drugH1Div" id="F58262663"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, hospital-acquired or ventilator-associated:</b> Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, in patients ≥18 years of age caused by susceptible isolates of <i>Acinetobacter baumannii-calcoaceticus</i> complex.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Not indicated for the treatment of pneumonia caused by pathogens other than susceptible isolates of <i>A. baumannii-calcoaceticus</i> complex.</p></div>
<div class="block mst drugH1Div" id="F58288953"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Sulbactam and durlobactam may be confused with ampicillin and sulbactam.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58280730"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F58280727"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Sulbactam. Management: Recommendations for management of this interaction vary by specific sulbactam-containing product. Coadministration of probenecid with sulbactam/durlobactam is not recommended, but no specific actions are recommended for ampicillin/sulbactam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F58289007"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Sulbactam crosses the human placenta. Outcome data following maternal use of sulbactam during pregnancy are available following use in combination with ampicillin.</p>
<p style="text-indent:0em;margin-top:2em;">Adverse events were observed in reproduction studies when durlobactam was administered SUBQ to pregnant mice in doses up to 4 times the maximum recommended human dose (MRHD) (based on AUC). Adverse events were not observed in reproduction studies when durlobactam was administered IV to pregnant rats in doses up to 4 times the MRHD.</p></div>
<div class="block brc drugH1Div" id="F58289008"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Sulbactam is present in breast milk; excretion of durlobactam is not known.</p>
<p style="text-indent:-2em;margin-left:2em;">A review article notes the exposure of sulbactam to a breastfeeding infant would be ~1% to 2% of a typical adult dose following administration in combination with ampicillin (Foulds 1986).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F58289062"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs of hypersensitivity reaction, including anaphylaxis and serious skin reactions. Regularly monitor kidney function.</p></div>
<div class="block pha drugH1Div" id="F58289033"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Sulbactam is a beta-lactam antibacterial and Ambler class A serine beta-lactamase inhibitor that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins 1 and 3. Durlobactam is a diazabicyclooctane beta-lactamase inhibitor that protects sulbactam from degradation by certain serine beta-lactamases.</p></div>
<div class="block phk drugH1Div" id="F58289038"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Sulbactam: V<sub>d</sub>: 25.4 ± 11.3 L; Durlobactam: V<sub>d</sub>: 30.3 ± 12.9 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Sulbactam: 38%; Durlobactam: 10%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimally metabolized.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Sulbactam: 2.15 ± 1.16 hours (when given with durlobactam); Durlobactam: 2.52 ± 0.77 hours. <b>Note:</b> Elimination kinetics of both sulbactam and durlobactam are similarly affected in patients with renal impairment; therefore, the blood concentration ratio is expected to remain constant regardless of renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Sulbactam: T<sub>max</sub>: 3.2 ± 0.6 hours; Durlobactam: T<sub>max:</sub> 3.1 ± 0.5 hours (Sagan 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Sulbactam: Urine (75% to 85% as unchanged drug); Durlobactam: Urine (78% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F58289046"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Altered kidney function: In patients with eGFR ≥60 to &lt;90 mL/minute/1.73 m<sup>2</sup>, AUCs of both sulbactam and durlobactam increased 1.4-fold. In patients with eGFR ≥30 to &lt;60 mL/minute/1.73 m<sup>2</sup>, AUC increased 2-fold for sulbactam and 1.9-fold for durlobactam. In patients with eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>, AUC increased 4.3-fold for sulbactam and 3.7-fold for durlobactam.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3025997">
<a name="3025997"></a>Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. <i>Rev Infect Dis</i>. 1986;8(suppl 5):S503-S511. doi:10.1093/clinids/8.supplement_5.503<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulbactam-and-durlobactam-drug-information/abstract-text/3025997/pubmed" id="3025997" target="_blank">3025997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521441">
<a name="27521441"></a>Kalil AC, Metersky ML, Klompas M, et al. Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):575-582. doi:10.1093/cid/ciw504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulbactam-and-durlobactam-drug-information/abstract-text/27521441/pubmed" id="27521441" target="_blank">27521441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37182534">
<a name="37182534"></a>Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). <i>Lancet Infect Dis</i>. Published online May 11, 2023. doi:10.1016/S1473-3099(23)00184-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulbactam-and-durlobactam-drug-information/abstract-text/37182534/pubmed" id="37182534" target="_blank">37182534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31843995">
<a name="31843995"></a>Sagan O, Yakubsevitch R, Yanev K, et al. Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis. <i>Antimicrob Agents Chemother</i>. 2020;64(3):e01506-19. doi:10.1128/AAC.01506-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sulbactam-and-durlobactam-drug-information/abstract-text/31843995/pubmed" id="31843995" target="_blank">31843995</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Xacduro (sulbactam and durlobactam) [prescribing information]. Waltham, MA: La Jolla Pharmaceutical Company; May 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 141569 Version 13.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
